Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for its use, such as to treat cancer.

Abstract: The present invention provides methods and compositions for treating biliary tract cancers by administering an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin. The present invention also provides combination treatment methods of treating biliary tract cancers comprising administering an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin and an effective amount of another therapeutic agent. Also provided herein are medicines and kits thereof.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: The present invention provides nomograms and methods or predicting survival probabilities for patients diagnosed with metastatic pancreatic cancer based upon patient characteristics such as neutrophil to lymphocyte ratio, albumin level, Karnofsky performance status, the sum of the longest diameter of target lesions, liver metastasis, previous Whipple procedure, treatment with nab-paclitaxel, and analgesic use. In some aspects, the nomograms or methods are implemented by a non-transitory computer-readable storage medium.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.

Abstract: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that antagonizes a PD-1 pathway in a cell.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.

Abstract: The present invention provides methods and compositions for treating pediatric solid tumor by administering a composition comprising nanoparticles that comprise a taxane and an albumin.

Abstract: Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.

Abstract: Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.

Abstract: Described herein are methods of treating cancer by administering a therapeutically effective amount of at least one texaphyrin metal complex or a pharmaceutically acceptable derivative, and performing stereotactic radiosurgery to the patient. In some embodiments, at least one texaphyrin metal complex or a pharmaceutically acceptable derivative is administered while the patient is undergoing a radiation therapy. Also described herein are methods for detecting various cancerous tumors, lesions, or metastases in a patient by administering an effective amount of at least one texaphyrin metal complex or a pharmaceutically acceptable derivative before a patient undergoes stereotactic radiosurgery. Also described herein are methods for visualizing tumors not otherwise visualized; methods for detecting the margins of a tumor; and methods for improving the targeting of the SRS radiation.